Fotios Tekos

Dr. Fotios Tekos

Biochemistry & Biotechnology, University of Thessaly, Larissa, Greece
orcid
CEO FoodOxys P.C. Spin-off, CEO Olea Fortius P.C., Contract ...

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 May 2020 in Molecular Medicine Reports
Verified
Journal Article
Open access
PDF file
DPDemetrios Petrakis
Demetrios Petrakis
Denisa MarginaDenisa Margina
Denisa Margina
Konstantinos TsarouhasKonstantinos Tsarouhas
Konstantinos Tsarouhas
Fotios TekosFotios Tekos
Fotios Tekos
MSMiriana Stan
Miriana Stan
Aristidis TsatsakisAristidis Tsatsakis
Aristidis Tsatsakis
Coronaviruses (CoVs), enveloped positive-sense RNA viruses, are a group of viruses that cause infections in the human respiratory tract, which can be characterized clinically from mild to fatal. The severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) is the virus responsible. The global spread of COVID‑19 can be described as the worst pandemic in humanity in the last century. To date, COVID‑19 has infected more than 3,000,000 people worldwide and killed more than 200,000 people. All age groups can be infected from the virus, but more serious symptoms that can possibly result in death are observed in older people and those with underlying medical conditions such as cardiovascular and pulmonary disease. Novel data report more severe symptoms and even a negative prognosis for the obese patients. A growing body of evidence connects obesity with COVID‑19 and a number of mechanisms from immune system activity attenuation to chronic inflammation are implicated. Lipid peroxidation creates reactive lipid aldehydes which in a patient with metabolic disorder and COVID‑19 will affect its prognosis. Finally, pregnancy‑associated obesity needs to be studied further in connection to COVID‑19 as this infection could pose high risk both to pregnant women and the fetus.

Denisa MarginaDenisa Margina
Denisa Margina
AUAnca Ungurianu
Anca Ungurianu
NPNicoleta Carmen Purdel
Nicoleta Carmen Purdel
Dimitris TsoukalasDimitris Tsoukalas
Dimitris Tsoukalas
Evangelia SarandiEvangelia Sarandi
Evangelia Sarandi
Aristidis TsatsakisAristidis Tsatsakis
Aristidis Tsatsakis
The lifestyle adopted by most people in Western societies has an important impact on the propensity to metabolic disorders (e.g., diabetes, cancer, cardiovascular disease, neurodegenerative diseases). This is often accompanied by chronic low-grade inflammation, driven by the activation of various molecular pathways such as STAT3 (signal transducer and activator of transcription 3), IKK (IκB kinase), MMP9 (matrix metallopeptidase 9), MAPK (mitogen-activated protein kinases), COX2 (cyclooxigenase 2), and NF-Kβ (nuclear factor kappa-light-chain-enhancer of activated B cells). Multiple intervention studies have demonstrated that lifestyle changes can lead to reduced inflammation and improved health. This can be linked to the concept of real-life risk simulation, since humans are continuously exposed to dietary factors in small doses and complex combinations (e.g., polyphenols, fibers, polyunsaturated fatty acids, etc.). Inflammation biomarkers improve in patients who consume a certain amount of fiber per day; some even losing weight. Fasting in combination with calorie restriction modulates molecular mechanisms such as m-TOR, FOXO, NRF2, AMPK, and sirtuins, ultimately leads to significantly reduced inflammatory marker levels, as well as improved metabolic markers. Moving toward healthier dietary habits at the individual level and in publicly-funded institutions, such as schools or hospitals, could help improving public health, reducing healthcare costs and improving community resilience to epidemics (such as COVID-19), which predominantly affects individuals with metabolic diseases.

6 June 2020 in Antioxidants
Verified
Journal Article
Open access
PDF file
FTFrançoise Wilhelmi de Toledo
Françoise Wilhelmi de Toledo
FGFranziska Grundler
Franziska Grundler
NGNikolaos Goutzourelas
Nikolaos Goutzourelas
Fotios TekosFotios Tekos
Fotios Tekos
EVEleni Vassi
Eleni Vassi
Dimitrios KouretasDimitrios Kouretas
Dimitrios Kouretas
Fasting is increasingly practiced to improve health and general well-being, as well as for its cytoprotective effects. Changes in blood redox status, linked to the development of a variety of metabolic diseases, have been recently documented during calorie restriction and intermittent fasting, but not with long-term fasting (LF). We investigated some parameters of the blood redox profile in 109 subjects before and after a 10-day fasting period. Fasting resulted in a significant reduction in body weight, improved well-being and had a beneficial modulating effect on blood lipids and glucose regulation. We observed that fasting decreased lipid peroxidation (TBARS) and increased total antioxidant capacity (TAC) in plasma, concomitant with a uric acid elevation, known to be associated with fasting and did not cause gout attacks. Reduced glutathione (GSH), glutathione reductase (GR), glutathione peroxidase (GPx) and catalase in erythrocytes did not show significant changes. In addition, reduction in body weight, waist circumference, and glucose levels were associated to a reduced lipid peroxidation. Similar results were obtained by grouping subjects on the basis of the changes in their GSH levels, showing that a period of 10 days fasting improves blood redox status regardless of GSH status in the blood.

28 August 2021 in Antioxidants
Verified
Journal Article
Open access
PDF file
VLVaia Lambadiari
Vaia Lambadiari
John ThymisJohn Thymis
John Thymis
Dimitrios KouretasDimitrios Kouretas
Dimitrios Kouretas
Zoi Vasiliki SkaperdaZoi Vasiliki Skaperda
Zoi Vasiliki Skaperda
Fotios TekosFotios Tekos
Fotios Tekos
Ignatios IkonomidisIgnatios Ikonomidis
Ignatios Ikonomidis
Imbalance between oxidative stress burden and antioxidant capacity is implicated in the course of atherosclerosis among type 2 diabetic patients. We addressed the effects of insulin, glucagon-like peptide-1 receptor agonists (GLP1-RA), sodium-glucose cotransporter-2 inhibitors (SGLT-2i), and their combination on levels of oxidant and antioxidant biomarkers. We recruited a total of 160 type 2 diabetics, who received insulin (n = 40), liraglutide (n = 40), empagliflozin (n = 40), or their combination (GLP-1RA+SGLT-2i) (n = 40). We measured at baseline, at 4 and at 12 months of treatment: (a) Thiobarbituric Acid Reactive Substances (TBARS), (b) Malondialdehyde (MDA), (c) Reducing Power (RP), (d) 2,2¢-azino-bis-(3-ethylbenzthiazoline-6-sulphonic acid) radical (ABTS) and (e) Total Antioxidant Capacity TAC). Dual treatment resulted in significant improvement of TBARS, MDA, and ABTS at four months compared with the other groups (p < 0.05 for all comparisons). At twelve months, all participants improved TBARS, MDA, and ABTS (p < 0.05). At 12 months, GLP1-RA and GLP-1RA+SGLT2-i provided a greater reduction of TBARS (−8.76% and −9.83%) compared with insulin or SGLT2i (−0.5% and 3.22%), (p < 0.05). GLP1-RA and GLP-1RA+SGLT-2i showed a greater reduction of MDA (−30.15% and −31.44%) compared with insulin or SGLT2i (4.72% and −3.74%), (p < 0.05). SGLT2i and GLP-1RA+SGLT2-i showed increase of ABTS (12.87% and 14.13%) compared with insulin or GLP1-RA (2.44% and −3.44%), (p < 0.05). Only combined treatment resulted in increase of TAC compared with the other groups after 12 months of treatment (p < 0.05).12-month treatment with GLP1-RA and SGLT2i resulted in reduction of biomarkers responsible for oxidative modifications and increase of antioxidant biomarker, respectively. The combination treatment was superior and additive to each separate agent and also the beneficial effects appeared earlier.

1 November 2020 in Food and Chemical Toxicology
Verified
Journal Article
Closed access
FGFranziska Grundler
Franziska Grundler
Robin MesnageRobin Mesnage
Robin Mesnage
NGNikolaos Goutzourelas
Nikolaos Goutzourelas
Fotios TekosFotios Tekos
Fotios Tekos
SMSotiria Makri
Sotiria Makri
FTFrançoise Wilhelmi de Toledo
Françoise Wilhelmi de Toledo

Verified
Journal Article
Open access
PDF file
Zoi Vasiliki SkaperdaZoi Vasiliki Skaperda
Zoi Vasiliki Skaperda
Fotios TekosFotios Tekos
Fotios Tekos
PVPeriklis Vardakas
Periklis Vardakas
CNCharitini Nepka
Charitini Nepka
Dimitrios KouretasDimitrios Kouretas
Dimitrios Kouretas
Cellular adaptive mechanisms emerging after exposure to low levels of toxic agents or stressful stimuli comprise an important biological feature that has gained considerable scientific interest. Investigations of low-dose exposures to diverse chemical compounds signify the non-linear mode of action in the exposed cell or organism at such dose levels in contrast to the classic detrimental effects induced at higher ones, a phenomenon usually referred to as hormesis. The resulting phenotype is a beneficial effect that tests our physiology within the limits of our homeostatic adaptations. Therefore, doses below the region of adverse responses are of particular interest and are specified as the hormetic gain zone. The manifestation of redox adaptations aiming to prevent from disturbances of redox homeostasis represent an area of particular interest in hormetic responses, observed after exposure not only to stressors but also to compounds of natural origin, such as phytochemicals. Findings from previous studies on several agents demonstrate the heterogeneity of the specific zone in terms of the molecular events occurring. Major factors deeply involved in these biphasic phenomena are the bioactive compound per se, the dose level, the duration of exposure, the cell, tissue or even organ exposed to and, of course, the biomarker examined. In the end, the molecular fate is a complex toxicological event, based on beneficial and detrimental effects, which, however, are poorly understood to date.